Fig. 3From: Oxaliplatin- versus cisplatin-based regimens for elderly individuals with advanced gastric cancer: a retrospective cohort studyPropensity score-weighted Kaplan–Meier survival curves for the two groups. These weighted Kaplan–Meier curves showed the overall survival of elderly patients with advanced gastric cancer treated with either oxaliplatin-based or cisplatin-based regimens. The median overall survival was 9.3 months (95% confidence interval, 7.1- Not Available months) and 12.4 months (95% confidence interval, 7.8–26.8 months) in the oxaliplatin-based and cisplatin-based treatment groups, respectively. The weighted log-rank test showed a p-value of 0.58. The hazard ratio was 1.13 (95% confidential interval, 0.60–2.11; p = 0.70)Back to article page